Hong Kong Stock Concept Tracking | Yao Ming Kangde once again raised 2026 annual results guidance agency: Continued optimism about the trend of innovative drugs going overseas (with concept stocks)

Zhitong Finance App learned that on the evening of October 26, Yao Ming Kangde announced that revenue for the third quarter was 16.640 billion yuan, up 38.01% year on year; net profit attributable to shareholders of listed companies was 8.318 billion yuan, up 136.67% year on year, and further raised the 2026 annual results guide. The company's overall revenue is expected to increase from 58.5 billion yuan to 60.5 billion yuan to 61 billion yuan to 61.9 billion yuan in 2026, and the year-on-year growth rate of continuing business revenue will increase from 35% to 39% to 40% to 42%.

Yao Ming Kangde said that the growth in performance was mainly due to the continuous focus on the CRDMO integrated business model: on the one hand, the proportion of late-stage and commercialized projects continued to rise, and early business achieved a sharp rise in volume and price, which directly led to an improvement in overall gross profit level; on the other hand, economies of scale under lean management continued to show, and operational efficiency improved steadily, jointly driving the profit-side growth rate significantly higher than the revenue side.

This is the fourth time in 16 months that Yakming Kangde has raised its annual business target. Previously, the company announced a comprehensive increase in its 2026 performance guidelines on August 3. It is estimated that the company's overall revenue will increase from 51.3 billion yuan to 53 billion yuan to 58.5 billion yuan to 58.5 billion yuan, and the year-on-year growth rate of continuing business revenue will increase from 18% to 22% to 35% to 39%. Since this year, Yao Ming Kangde's on-hand orders have successively broken through the 60 billion and 70 billion mark, continuing to set new records. As of the end of September 2026, its ongoing business orders climbed to 76.74 billion yuan, an increase of 36.4% over the previous year.

On the same day, Hanyu Pharmaceutical announced that revenue for the third quarter was 554 million yuan, up 314.48% year on year; net profit attributable to shareholders of listed companies was 200 million yuan, up 369.76% year on year. Revenue for the first three quarters was 1,242 billion yuan, up 81.87% year on year; net profit attributable to shareholders of listed companies was 437 million yuan, up 511.96% year on year. The increase in revenue is due to an increase in the company's API sales revenue.

In recent years, the global CXO industry as a whole has shown a steady trend of expansion. According to the J.P. Morgan Chase report, in the first three quarters of 2026, the amount disclosed in global biomedical R&D licensing transactions was 221.1 billion US dollars, reaching 80% of the record level for the full year of 2025; the total down payment and equity consideration for biomedical mergers and acquisitions was 138.9 billion US dollars, surpassing the full year of 2025. According to Pharmaceutical Rubik's Cube data, the total amount of Chinese pharmaceutical overseas transactions in the first three quarters of 2026 reached 131.3 billion US dollars, which is close to the total transaction amount of 135.7 billion US dollars for the whole year of 2025.

Guojin Securities said that against the backdrop of multinational pharmaceutical companies' core product patents expiring and pipeline supplementation demand continuing to be released, it continues to be optimistic about the trend of innovative drugs going overseas. It is recommended to focus on active BD tracks such as dual antibodies, ADC, and micronucleic acids, as well as innovative drug companies with intensive clinical data catalytic activity and continuous promotion of overseas cooperation. Innovative pharmaceutical companies are about to reach a point where they will reverse their performance. Clinical data is catalytically intensive throughout the year. Combined with overseas clinical pipelines, overseas clinical progress is progressing smoothly, and investment opportunities in the sector are clear.

Related concept stocks:

Yao Ming Kangde (02359): Yao Ming Kangde announced that revenue for the third quarter was 16.640 billion yuan, up 38.01% year on year; net profit attributable to shareholders of listed companies was 8.318 billion yuan, up 136.67% year on year.

Gloria Ying (06821): According to the 2026 three-quarter report released by Gloria Ying, the company achieved operating income of about 5.395 billion yuan, an increase of 16.52% over the previous year, and attributable net profit of about 852 million yuan, an increase of 6.49% over the previous year.

Kanglong Chemical (03759): In mid-2026, the company achieved operating revenue of 7.595 billion yuan, an increase of 17.9% over the previous year; shareholders should account for profit of 750 million yuan, an increase of 7.0% over the previous year. Of this, revenue of 4,017 billion yuan was achieved in the second quarter, and profit attributable to shareholders was 415 million yuan.

Yao Ming Biotech (02269): In the first half of 2026, the company achieved revenue of 11.787 billion yuan, up 18.4% year on year; gross profit of 5.448 billion yuan, up 28.1% year on year, gross margin increased 3.5 percentage points to 46.2%; net profit of 2,440 billion yuan, up 4.3% year on year.